Immunotherapy is at a strategic point, according to Caroline Robert (Gustave Roussy, Paris). Speaking at the opening plenary session of the European Cancer Congress (25–29 September 2015), she said that future developments will come from the fields of genomics and immunotherapy – and others – working together.
The tumours with the highest load of somatic mutations, such as melanoma and lung cancers, may be the ones that present most new antigens to the immune system, she said. So the cancers which have been most difficult to treat may in the end respond best to immunotherapy.
In this EJC News Focus, Caroline Robert explains more about the science and its implications to Helen Saul.
Page last modified: